MYMAN is spending HTDS money on the ladies this weekend, my man

MYMAN rates MedaSorb Technologies (MSBT) a BUY

Currently trading at 0.0650, my man.

This here is a bouncy bouncy stock that goes up and down this one here ready for bounce-up, my man. It was as high as 12 cents as recently as June 5th, my man.

Quick profile: Medasorb Technologies Corporation, a development stage medical device company, focuses on developing and commercializing blood purification technologies that would remove middle molecular weight toxins from circulating blood and physiologic fluids.

MYMAN's quick picks, my man

Got some money to invest, my man? You won't go wrong if you invest that money in some of these, my man:

AMNE
ANPI
BIEL
CTIC
CPSL
GBH
HNAB
HTDS
IMMU
PDMI
MDFI
VRAL
ARTI
HEB
HGSI
INO
IDOI
SMWF
NEPH

MYMANS Darkhorse Pick: Immtech Pharmaceuticals, my man

MYMAN is not expressing an opinion on Immtech Pharmaceuticals (IMMP) but he is checking them out. They had a failed drug a couple of years ago but they are still around and cheap, my man. Gonna take a look at them and see what they're doing, my man.

Currently trading at 0.1735

Quick profile: Immtech Pharmaceuticals, Inc. focuses on the discovery and development of drugs to treat infectious diseases worldwide. The company involves in drug discovery and development programs for hepatitis C and malaria; and provides aromatic cationic pharmaceutical compounds. It also offers assistance to healthcare companies seeking to conduct clinical trials, and manufacture and/or distribute pharmaceutical products in China

I don't know about you my man, but this do have my interest, my man.

ADLS denied! MYMAN is right again, my man

Yes, my man.

Fraud of the day: Advanced Life Sciences Holdings (ADLS), my man

NO FDA approval, now down below fifty cent, my man.

I told you, my man.

Here's why the FDA turned down Advanced Life Sciences Holdings (ADLS) and Cethromycin, my man

MYMAN has been warning his readers about ADLS about upcoming FDA disapproval of ADLS, my man.

ADLS has a drug called Cethromycin which claims to be a ketolide antibiotic but as everbody knows my man, ketolides are antibiotics that are belonging to the macrolide group, my man.

MYMAN has been studying all about this, my man and he can tell you that macrolide groups are not stable with FEV1, sputum interleukin 6 (IL-6), IL-8, myeloperoxidase, bacterial flora, serum C-reactive protein, or serum IL-6 or in changes in these parameters from baseline to the first exacerbation, my man.

In addition, MYMAN discovered that Cethromycin was initially known as ABT-773, my man turns out that ABT stands for 'Attempted' Biotechnesis Trial' which tells MYMAN that Cethromycin is not a completed drug, my man.

MY MAN rates Hana Biosciences (Nasdaq: HNAB) a buy, my man.

Click on image above for resolution, my man

MY MAN feels bad about this one because HNAB was hanging around twenty cent fo' a long time, damn, my man. MY MAN got 100 shares of this shortie a long time ago and forgot all about it, my man.

But Sheeeeeeeeeeeeeeeeeeeeeeit (click here) it's climbing up and MY MAN thinks HNAB has got the potential to go a lot higher, my man.

This here be their site, my man

Now look here now:

NEW YORK, July 21 (Reuters) - Gambling on volatile small-cap biotechnology companies can be gut wrenching even in the best of times, but wild stock jumps based on positive clinical data may tempt investors to give them a second look with the hope of catching that really big payoff.

Human Genome Sciences Inc this week provided the latest golden carrot that investors may follow back into the sector.

But John McCamant, editor of the Medical Technology Stock Letter, is preaching diversification by investing in companies of varying sizes and with different technologies while staying away from companies with cash problems.

"You need to diversify because some of these are still going to blow up. If Human Genome didn't win, it was probably going to go down 50-plus percent," McCamant said.

McCamant also suggested keeping an eye on any company that lands former top Genentech talent after that company's purchase by Roche. He noted that Human Genome's current head of research and development came from Genentech.

He mentioned MicroMet Inc, Amicus Therapeutics Inc, Hana Biosciences Inc and Allos Therapeutics Inc as potential small biotech basket options. Becker said he does not have any long or short positions in the companies he discussed.


Here's the whole damn thing, my man.

MY MAN, says yes

Hard To Treat Diseases: MY MAN is proven right again, my man

Yeah, baby. Now that's what MY MAN wants to see!

Make me the CEO of Hemispherx BioPharma, my man

Nobody is happy with HEB, my man. We want money, not delay, my man. Time for change, my man so therefore I nominate myself, MYMAN to be the new CEO of Hemispherx BioPharma, my man. I will treat you right and I will not lie to you, my man. MYMAN is serious about one thing and one thing only: making money and the being with the ladies, my man.

MYMAN rates Hard To Treat Diseases, (HTDS), a BUY, my man

This one has very good potential, my man. Buy it now when it be dirt-cheap, my man. Make no mistake: MY MAN say this will take off, my man.

Time to look at CNBC’s Melissa Lee, my man

Get into HGSI, my man.

HGSI is delivering the G $$$, my man.

"id give it to her hard and she would take it "

Make money my man

Human Genome lupus drug succeeds in clinical trial, my man

TIME TO BUY HGSI IS NOW, MY MAN:

Human Genome lupus drug succeeds in clinical trial

BOSTON, July 20 (Reuters) - Human Genome Sciences Inc (HGSI.O) said on Monday its experimental drug to treat lupus was successful in a late-stage clinical trial, a likely shock to many on Wall Street who had written the drug off as dead.

The results, which were announced just after midnight on Sunday, showed patients who took the drug, Benlysta, showed a statistically significant improvement in the symptoms of their disease compared to those taking a placebo.

Results of the 52-week trial -- the first of two requested by U.S. regulators -- showed 57.6 percent of patients taking a high dose of Benlysta experienced an improvement in their symptoms, compared with 43.6 percent who took a placebo.

The result was statistically significant and met the main goal of the clinical trial.

Of patients who took a low dose of the drug, which is administered once a month by IV infusion, 51.7 percent showed improvement in their symptoms, a figure that was also statistically significant.

The main goal of the trial was to show a four-point or greater improvement in disease symptoms as measured by a scale known as Selena Sledai. A four-point reduction on a scale of 10 constitutes a good, or meaningful, response. The lower the score the less disease activity a patient has. All patients entering the trial had a score of six or higher.

The trial also required that patients did not experience a worsening of their disease in any organ beyond the originally affected one. The trial met all of these goals at both doses.

Lupus is a complex autoimmune disease that causes the immune system to attack the body's own tissue and organs, including the joints, kidneys, heart, lungs, brain, blood or skin. Symptoms include achy joints, fever, arthritis, kidney damage, chest pain and skin rash, among others.

Data from the 867-person trial, known as BLISS-52, take the company one step closer to being the first to have a new lupus drug approved in 50 years. There are multiple drugs that are approved for other indications and used to treat lupus, but no drug has been approved specifically for lupus in decades.

It is estimated that 1.5 million people in the United States and 5 million worldwide are affected by lupus, according to the Lupus Foundation of America.

Human Genome's drug is not expected to treat all patients. It is aimed at a subgroup of patients who have mild to moderate disease. That is because an earlier trial failed to meet its main goal, but investigators noticed that a subset of patients did very well.

The late-stage, or Phase III, trials were designed in conjunction with the U.S. Food and Drug Administration, to test those patients most likely to benefit from the drug.

The initial market for the Benlysta, therefore, consists of some 300,000 patients, said Thomas Watkins, the company's chief executive, in an interview. Roughly 150,000 patients in the United States stand to benefit from the drug, if it is approved.

MY MAN rates the Blackstone Group as a BUY, my man

NYSE: BX

Time for some Billy Preston, my man

Samuel L. Jackson to the FDA: Approve Ampligen Motherfu**kers!

Hemispherx BioPharma, (HEB) will close at $2.25 on July 9, my man

Don't worry, my man.

MY MAN, was right again! Viral Genetics, Inc. (VRAL), my man

This sucka soared today, my man.

Hemispherx BioPharma (AMEX:HEB) at $25 a share?!

Stay tuned, my man!

Labopharm Inc is rated a BUY by MY MAN

Labopharm Inc (DDSS) is expected to get FDA approval on or around July 18th. This is rated a BUY, my man. Also check out Viral Genetics (VRAL) my man!

I made some good money this week on BIEL, my man

I'm treating myself to Arby's, my man.